secwatch.observer — SEC 8-K summary
======================================

Issuer:     NOVAVAX INC (NVAX)
CIK:        0001000694
Form:       8-K
Filed at:   2023-12-05T23:59:59+00:00
Accession:  0001104659-23-123481
Event type: litigation
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Novavax reaches $47M settlement in principle to resolve securities class action
-------------------------------------------------------------------------------

- Company agreed to pay $47M into settlement fund; expects D&O insurance to fund it.
- Settlement resolves surviving claims about alleged false statements on vaccine manufacturing and regulatory approval.
- Class period: February 24, 2021 to October 19, 2021; court approval required.
- Settlement includes customary releases and a disclaimer of liability by Novavax and named executives.
- Previously, court dismissed some claims but allowed others to proceed; parties now seek to end litigation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1000694/000110465923123481/0001104659-23-123481-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1000694/000110465923123481/tm2332186d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-123481

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer